TB-500

No study cited here gave TB-500 to a person, and FDA says it has not identified any human exposure data for the substance. TB-500 is a short synthetic fragment, the acetylated 17-23 stretch of thymosin beta-4 (Ac-LKKTETQ), and it draws attention because the parent protein has a well-documented role in cell migration and wound repair in rats and in cell culture.

The catch is that every repair finding behind the name was produced with full-length thymosin beta-4, not the fragment. The one paper that deals with TB-500 itself is an anti-doping laboratory confirming which molecule was in a product sold under that name. The biology is real. None of it has been measured for the fragment.

Thymosin beta-4 is a 4.9 kDa polypeptide that interacts with G-actin, the single-unit form of actin, and is thought to mediate cell proliferation, migration and differentiation. TB-500 is not that protein. When Esposito and colleagues analysed a TB-500 formulation in 2012, they identified the N-terminal acetylated 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ: seven amino acids with an acetyl group on the front end. They then built the fragment by solid-phase peptide synthesis and proposed a method for detecting it in plasma and urine.

The two names are easy to blur, so FDA's own wording is worth having: its listing reads "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500."

What the Parent Protein Does

A 2005 review by Goldstein, Hannappel and Kleinman calls thymosin beta-4 the major actin-sequestering molecule in eukaryotic cells and links it to dermal and corneal wound healing. The experimental work behind that is specific.

In human umbilical vein endothelial cells, thymosin beta-4 acted as a chemoattractant, raising migration in Boyden chambers four- to sixfold over medium alone and speeding the closure of a scratch wound across the cell layer. Of the primary cell types tested, only human coronary artery cells responded, which the authors took as an endothelial-specific effect. Treated cells also produced more matrix metalloproteinases, enzymes that can degrade basement membrane during new vessel growth. In a rat full-thickness skin wound, thymosin beta-4 increased reepithelialization, collagen deposition and angiogenesis, and in culture it stimulated keratinocyte migration two- to threefold.

Where the Fragment Fits

None of those experiments used Ac-LKKTETQ. No cited study tests whether the seven-residue fragment binds actin, draws endothelial cells, or closes a wound on its own. Whether it carries any of the parent protein's activity is an open question, not a finding, and the mechanism above describes thymosin beta-4 only.

Borrowing the parent protein's results. The rat wound and endothelial cell findings came from thymosin beta-4. Citing them for TB-500 assumes a seven-residue piece does what the whole protein does, and no cited work tested that.

Reading a forecast as a result. The 2005 review lists "potential clinical applications" for thymosin beta-4 in tissue repair after myocardial infarction and stroke, and possible roles in septic shock. Those are proposals about the parent protein, not measured outcomes, and not claims about the fragment.

Treating an identity paper as validation. Esposito 2012 shows which molecule was in the formulation its authors analysed. It says nothing about whether the molecule does anything, and it vouches for the contents of that product, not for every vial carrying the name.

Unknown in humans. FDA's published assessment reads: "Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

Regulatory status. TB-500 left FDA Category 2 on or about 22 April 2026 because the nominators withdrew the nomination, not because FDA resolved its safety concerns, and those concerns remain published under FDA's list of bulk drug substances nominated but withdrawn. It is on neither FDA list now and is not an FDA-approved drug. FDA's Pharmacy Compounding Advisory Committee reviewed it at the meeting of 23-24 July 2026. FDA has published the agenda, the roster, the voting questions and its own presentation slides, but no minutes, transcript or written vote tally, so no outcome can be stated. A committee recommendation is not an FDA decision and would not change legal status by itself; rulemaking on the full record decides that.

The fair summary is narrow. Thymosin beta-4 has a documented record in rat skin wounds and in human endothelial and keratinocyte cultures: faster wound closure, more collagen, more vessel growth, more cell migration. TB-500 borrows that record by name. Its own record is a chemistry paper and an FDA statement that no human exposure data have been identified.

For someone interested in tissue repair, the parent protein's biology explains why the name gets attention. It cannot tell anyone what the fragment does in a tendon, a muscle or a person, how often it causes harm, or whether a given product matches the fragment the 2012 laboratory found.

Not thymosin beta-4. It is a seven-residue acetylated piece of it, and the wound and vessel results belong to the whole protein.

Not a tested repair agent. No experiment cited here measured TB-500 healing anything, in an animal, in a dish or in a person.

Not allowed in tested sport. WADA prohibits it under S2.3, Growth Factors, where the list names "Thymosin-B4 and its derivatives, e.g. TB-500". It is named outright, so there is no ambiguity for a tested athlete.

Not settled by the July 2026 advisory meeting. No outcome has been published, and an advisory committee does not decide legal status.

I find thymosin beta-4 genuinely interesting. A protein cells use to manage actin turning out to pull endothelial cells toward it and speed rat wound reepithelialization by 42 to 61 percent is the kind of biology that earns a second look.

TB-500 is a different question, and the name hides that. For the fragment itself, what I can point to is a mass spectrometry paper and an FDA statement that it has found no human exposure data. I am not going to dress the parent protein's results up as the fragment's, and I am not going to treat a product label as proof of what is inside it. A controlled study of Ac-LKKTETQ itself would change my view. Until one exists, the honest description is a fragment of a well-studied protein with no measured effects of its own that I can cite.